

Jae Yong Cho

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/2838562/jae-yong-cho-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

60
papers

4,720
citations

27
h-index

61
g-index

61
ext. papers

5,771
ext. citations

6.3
avg, IF

4.87
L-index

#	Paper	IF	Citations
60	Application of CRISPR/Cas9-based mutant enrichment technique to improve the clinical sensitivity of plasma EGFR testing in patients with non-small cell lung cancer.. <i>Cancer Cell International</i> , 2022 , 22, 82	6.4	0
59	Impact of the Double Mutants on Spike Protein of SARS-CoV-2 B.1.617 Lineage on the Human ACE2 Receptor Binding: A Structural Insight. <i>Viruses</i> , 2021 , 13,	6.2	3
58	Nivolumab in previously treated advanced gastric cancer (ATTRACTION-2): 3-year update and outcome of treatment beyond progression with nivolumab. <i>Gastric Cancer</i> , 2021 , 24, 946-958	7.6	13
57	Detection of fusion in cell-free DNA of a patient with advanced gastric cancer: A case report. <i>World Journal of Clinical Cases</i> , 2021 , 9, 2884-2889	1.6	1
56	A phase 3 study of nivolumab in previously treated advanced gastric or gastroesophageal junction cancer (ATTRACTION-2): 2-year update data. <i>Gastric Cancer</i> , 2020 , 23, 510-519	7.6	72
55	Exploratory subgroup analysis of patients with prior trastuzumab use in the ATTRACTION-2 trial: a randomized phase III clinical trial investigating the efficacy and safety of nivolumab in patients with advanced gastric/gastroesophageal junction cancer. <i>Gastric Cancer</i> , 2020 , 23, 143-153	7.6	26
54	A phase I/II study of poziotinib combined with paclitaxel and trastuzumab in patients with HER2-positive advanced gastric cancer. <i>Gastric Cancer</i> , 2019 , 22, 1206-1214	7.6	17
53	Efficacy and tolerability of ramucirumab monotherapy or in combination with paclitaxel in gastric cancer patients from the Expanded Access Program Cohort by the Korean Cancer Study Group (KCSG). <i>Gastric Cancer</i> , 2018 , 21, 819-830	7.6	15
52	Subgroup analysis of East Asian patients in REGARD: A phase III trial of ramucirumab and best supportive care for advanced gastric cancer. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2018 , 14, 204-209	1.9	5
51	Clinical and genomic landscape of gastric cancer with a mesenchymal phenotype. <i>Nature Communications</i> , 2018 , 9, 1777	17.4	116
50	Efficacy of adjuvant chemotherapy for completely resected stage IB non-small cell lung cancer: a retrospective study. <i>Journal of Thoracic Disease</i> , 2018 , 10, 2279-2287	2.6	9
49	Clinical trial of nintedanib in patients with recurrent or metastatic salivary gland cancer of the head and neck: A multicenter phase 2 study (Korean Cancer Study Group HN14-01). <i>Cancer</i> , 2017 , 123, 1958-1964	6.4	28
48	Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet, The</i> , 2017 , 390, 2461-2471	40	1123
47	Prognostic Factor Analysis of Overall Survival in Gastric Cancer from Two Phase III Studies of Second-line Ramucirumab (REGARD and RAINBOW) Using Pooled Patient Data. <i>Journal of Gastric Cancer</i> , 2017 , 17, 132-144	3.2	36
46	Clinical Significance of Four Molecular Subtypes of Gastric Cancer Identified by The Cancer Genome Atlas Project. <i>Clinical Cancer Research</i> , 2017 , 23, 4441-4449	12.9	213
45	Efficacy of Sequential Ipilimumab Monotherapy versus Best Supportive Care for Unresectable Locally Advanced/Metastatic Gastric or Gastroesophageal Junction Cancer. <i>Clinical Cancer Research</i> , 2017 , 23, 5671-5678	12.9	91
44	Ramucirumab as Second-Line Treatment in Patients With Advanced Hepatocellular Carcinoma: Analysis of REACH Trial Results by Child-Pugh Score. <i>JAMA Oncology</i> , 2017 , 3, 235-243	13.4	59

43	Comparison of capecitabine and oxaliplatin with S-1 as adjuvant chemotherapy in stage III gastric cancer after D2 gastrectomy. <i>PLoS ONE</i> , 2017 , 12, e0186362	3.7	10
42	Survival analysis based on human epidermal growth factor 2 status in stage II-III gastric cancer. <i>World Journal of Gastroenterology</i> , 2017 , 23, 7407-7414	5.6	9
41	Subgroup analysis of East Asians in RAINBOW: A phase 3 trial of ramucirumab plus paclitaxel for advanced gastric cancer. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2016 , 31, 581-9	4	31
40	Phase II trial of dacomitinib in patients with HER2-positive gastric cancer. <i>Gastric Cancer</i> , 2016 , 19, 1095-1103	4.1	26
39	Overexpression of Endoplasmic Reticulum Oxidoreductin 1- α (ERO1L) Is Associated with Poor Prognosis of Gastric Cancer. <i>Cancer Research and Treatment</i> , 2016 , 48, 1196-1209	5.2	27
38	Development and Validation of a Six-Gene Recurrence Risk Score Assay for Gastric Cancer. <i>Clinical Cancer Research</i> , 2016 , 22, 6228-6235	12.9	17
37	Randomized, Double-Blind Phase II Trial With Prospective Classification by ATM Protein Level to Evaluate the Efficacy and Tolerability of Olaparib Plus Paclitaxel in Patients With Recurrent or Metastatic Gastric Cancer. <i>Journal of Clinical Oncology</i> , 2015 , 33, 3858-65	2.2	202
36	Comparison of Surgery Plus Chemotherapy and Palliative Chemotherapy Alone for Advanced Gastric Cancer with Krukenberg Tumor. <i>Cancer Research and Treatment</i> , 2015 , 47, 697-705	5.2	32
35	Gemcitabine Combined with Capecitabine Compared to Gemcitabine with or without Erlotinib as First-Line Chemotherapy in Patients with Advanced Pancreatic Cancer. <i>Cancer Research and Treatment</i> , 2015 , 47, 266-73	5.2	6
34	Treatment of a Patient with Kaposi's Sarcoma Arising during Hemodialysis with the Multikinase Inhibitor Pazopanib. <i>Korean Journal of Medicine</i> , 2015 , 89, 113	0.5	
33	Addition of docetaxel to S-1 without platinum prolongs survival of patients with advanced gastric cancer: a randomized study (START). <i>Journal of Cancer Research and Clinical Oncology</i> , 2014 , 140, 319-28	4.9	132
32	Targeted therapy in gastric cancer: personalizing cancer treatment based on patient genome. <i>World Journal of Gastroenterology</i> , 2014 , 20, 2042-50	5.6	15
31	Clinicopathologic implications of the BRAF(V600E) mutation in papillary thyroid cancer: a subgroup analysis of 3130 cases in a single center. <i>Thyroid</i> , 2013 , 23, 1423-30	6.2	83
30	Molecular diagnosis for personalized target therapy in gastric cancer. <i>Journal of Gastric Cancer</i> , 2013 , 13, 129-35	3.2	49
29	Overexpression of miR-196b and HOXA10 characterize a poor-prognosis gastric cancer subtype. <i>World Journal of Gastroenterology</i> , 2013 , 19, 7078-88	5.6	54
28	A Case of Adenocarcinomatous Transformation of a Sacrococcygeal Teratoma in an Adult. <i>Korean Journal of Medicine</i> , 2013 , 85, 101	0.5	
27	Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial. <i>Lancet, The</i> , 2012 , 379, 315-21	40	1085
26	Treatment outcome of patients with anaplastic thyroid cancer: a single center experience. <i>Yonsei Medical Journal</i> , 2012 , 53, 352-7	3	46

25	AMPK modulation in cancer progression: multilayer integrative analysis of the whole transcriptome in Asian gastric cancer. <i>Cancer Research</i> , 2012 , 72, 2512-21	10.1	82
24	Comparison of two inflammation-based prognostic scores in patients with unresectable advanced gastric cancer. <i>Oncology</i> , 2012 , 83, 292-9	3.6	66
23	Overexpression of the M2 isoform of pyruvate kinase is an adverse prognostic factor for signet ring cell gastric cancer. <i>World Journal of Gastroenterology</i> , 2012 , 18, 4037-43	5.6	62
22	Thioredoxin and thioredoxin-interacting protein as prognostic markers for gastric cancer recurrence. <i>World Journal of Gastroenterology</i> , 2012 , 18, 5581-8	5.6	39
21	A Case of Adenocarcinoma Arising within Intra-Abdominal Bronchogenic Cyst. <i>Korean Journal of Medicine</i> , 2012 , 82, 374	0.5	
20	Antifibrotic effects of magnesium lithospermate B on hepatic stellate cells and thioacetamide-induced cirrhotic rats. <i>Experimental and Molecular Medicine</i> , 2011 , 43, 341-9	12.8	30
19	Gene expression signature analysis identifies vorinostat as a candidate therapy for gastric cancer. <i>PLoS ONE</i> , 2011 , 6, e24662	3.7	83
18	Gene expression signature-based prognostic risk score in gastric cancer. <i>Clinical Cancer Research</i> , 2011 , 17, 1850-7	12.9	232
17	Prognostic factors of second and third line chemotherapy using 5-fu with platinum, irinotecan, and taxane for advanced gastric cancer. <i>Cancer Research and Treatment</i> , 2011 , 43, 236-43	5.2	12
16	Outcome of adjuvant therapy for gallbladder cancer. <i>Oncology</i> , 2010 , 79, 168-73	3.6	26
15	Prognostic biomarkers for esophageal adenocarcinoma identified by analysis of tumor transcriptome. <i>PLoS ONE</i> , 2010 , 5, e15074	3.7	106
14	Oxaliplatin combined with continuous infusion of 5-fluorouracil as first-line chemotherapy in patients with metastatic or recurrent gastric adenocarcinoma. <i>Chemotherapy</i> , 2009 , 55, 200-6	3.2	6
13	Gemcitabine and oxaliplatin combination as first-line treatment for advanced pancreatic cancer: a multicenter phase II study. <i>Cancer Chemotherapy and Pharmacology</i> , 2009 , 64, 317-25	3.5	15
12	Erlotinib monotherapy for stage IIIB/IV non-small cell lung cancer: a multicenter trial by the Korean Cancer Study Group. <i>Journal of Thoracic Oncology</i> , 2009 , 4, 1136-43	8.9	23
11	Phase II trial of oxaliplatin combined with leucovorin and fluorouracil for recurrent/metastatic biliary tract carcinoma. <i>Anti-Cancer Drugs</i> , 2008 , 19, 631-5	2.4	10
10	A phase II study of capecitabine plus gemcitabine in patients with locally advanced or metastatic pancreatic cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2008 , 62, 763-8	3.5	12
9	Non-Hodgkin's lymphoma of the sphenoid sinus presenting as isolated oculomotor nerve palsy. <i>World Journal of Surgical Oncology</i> , 2007 , 5, 86	3.4	27
8	Docetaxel-induced onycholysis: the role of subungual hemorrhage and suppuration. <i>Yonsei Medical Journal</i> , 2007 , 48, 124-6	3	17

7	Salvage chemotherapy with docetaxel and epirubicin for advanced/metastatic gastric cancer. <i>Oncology</i> , 2007 , 73, 2-8	3.6	6
6	9-cis retinoic acid induces insulin-like growth factor binding protein-3 through DR-8 retinoic acid responsive elements. <i>Cancer Biology and Therapy</i> , 2006 , 5, 586-92	4.6	9
5	Capecitabine combined with gemcitabine (CapGem) as first-line treatment in patients with advanced/metastatic biliary tract carcinoma. <i>Cancer</i> , 2005 , 104, 2753-8	6.4	86
4	Evaluation of E1B gene-attenuated replicating adenoviruses for cancer gene therapy. <i>Cancer Gene Therapy</i> , 2002 , 9, 725-36	5.4	66
3	Relationship between p53 overexpression and gastric cancer progression. <i>Oncology</i> , 1997 , 54, 166-70	3.6	17
2	Retrospective comparison of infusional 5-fluorouracil, doxorubicin, and mitomycin-C (modified FAM) combination chemotherapy versus palliative therapy in treatment of advanced gastric cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 1997 , 20, 484-9	2.7	10
1	Overexpression of c-ErbB-2 protein in gastric cancer by immunohistochemical stain. <i>Oncology</i> , 1996 , 53, 192-7	3.6	27